During the corresponding time, Viridian Therapeutics Inc recorded a revenue increase by 95.83 % year on year, sequentially revenue grew by 16.53 %. While revenue at the Viridian Therapeutics Inc 's corporate clients
Viridian Therapeutics Inc's Comment on Sales, Marketing and Customers
The company is developing elegrobart, a subcutaneous anti-IGF-1R antibody auto-injector for patients with active and chronic Thyroid Eye Disease (TED). Two global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, are underway to evaluate the efficacy and safety of elegrobart in these conditions. The trials involve subcutaneous administration every four or eight weeks and aim to support regulatory approval for marketing. Enrollment for both trials was completed in September 2025, exceeding targets due to strong patient demand. A phase 1 trial in healthy volunteers demonstrated that elegrobart has an extended half-life of 40 to 50 days, is well tolerated, and allows dosing flexibility. The company is also developing an auto-injector device for potential commercial launch. The primary market focus is on patients with active and chronic TED, emphasizing convenient, less frequent, low-volume at-home treatment options.
Viridian Therapeutics to Unveil Phase 3 Results for Promising Treatment of Chronic TED In a highly anticipated announcement, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company with a concentrated focus on severe and rare diseases, revealed its plans to broadcast the topline results from its Phase 3 THRIVE-2 clinical trial. Throughout the biotech community and among investors, this development has sparked considerable attention due to the potential impacts on treatment approaches for Thyroid Eye Disease (TED), a condition affecting approximately 16 in every 100,000 people annually.The webcast, scheduled for December 16, 2024, at 8:00 a.m. Eastern Time, represents a pivotal moment in Virid...
Viridian Therapeutics Set to Unveil Pivotal Data on VRDN-001 A Game-Changer in Treatment for Thyroid Eye DiseaseWALTHAM, Mass. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a trailblazer in the biopharmaceutical arena, is gearing up to present critical topline data from its THRIVE Phase 3 clinical trial evaluating VRDN-001, a potential best-in-class therapy for patients grappling with active Thyroid Eye Disease (TED). The highly anticipated conference call and webcast will take place on September 10, 2024, at 8:00 AM ET, marking a significant milestone for both the company and the healthcare community.In a sector that constantly seeks innovative solutions for rare and serious conditions, Viridian’s entry int...
Recently, Viridian Therapeutics, a leading biotechnology company dedicated to the development of innovative medicines for serious and rare diseases, announced their participation in the prestigious 42nd Annual J.P. Morgan Healthcare Conference. The event, held in San Francisco, California, serves as a platform for industry leaders to showcase their progress and discuss future strategies.During the conference, Steve Mahoney, the President and Chief Executive Officer of Viridian Therapeutics, will deliver a comprehensive presentation on the company s recent achievements and outline their key corporate priorities for the year 2024. The emphasis will be on Viridian s commitment to discovering and developing pote...
Viridian Therapeutics Inc., a pioneering biotech corporation with a focus on the development of innovative medicines for severe and rare illnesses, has announced VRDN-003 as their leading subcutaneous (SC) program for thyroid eye disease (TED) after achieving promising clinical data from a Phase 1 investigation in healthy subjects. This landmark announcement represents a significant stride in Viridian’s unceasing pursuit to provide groundbreaking solutions for rare diseases. The Waltham, Massachusetts based organization’s selection of VRDN-003 follows positive data gathered from the healthy volunteer study. Particularly striking was the revelation of VRDN-003’s extended half-life, which was ob...
Viridian Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company is developing elegrobart, a subcutaneous anti-IGF-1R antibody auto-injector for patients with active and chronic Thyroid Eye Disease (TED). Two global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, are underway to evaluate the efficacy and safety of elegrobart in these conditions. The trials involve subcutaneous administration every four or eight weeks and aim to support regulatory approval for marketing. Enrollment for both trials was completed in September 2025, exceeding targets due to strong patient demand. A phase 1 trial in healthy volunteers demonstrated that elegrobart has an extended half-life of 40 to 50 days, is well tolerated, and allows dosing flexibility. The company is also developing an auto-injector device for potential commercial launch. The primary market focus is on patients with active and chronic TED, emphasizing convenient, less frequent, low-volume at-home treatment options.
Sources:
Viridian Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Viridian Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Viridian Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
-4.26 %